AD: Alzheimer's disease; HEK: Human embryonic kidney; phospho-tau: phosphorylated tau; PHF: paired helical filament; EGFP: enhanced green fluorescent protein; iRFP: infrared fluorescent protein; λ P P : lambda protein phosphatase; WT: wild-type; GSK-3β: PTM: post-translational modification; glycogen synthase kinase-3β; scFv: single-chain antibody variable fragment; pThr231: phospho-threonine 231, RRID: Research Resource Identifier.
Introduction
Site-specific phosphorylation of the microtubule-associated protein tau is a well-defined molecular signature linked to normal tau function as well as pathology in neurodegeneration. Antibodies binding to phosphorylated tau (phospho-tau) are extensively used in research and being adopted in clinical diagnosis (Chai et al. 2011; Boutajangout et al. 2011; Kayed 2010; Asuni et al. 2007; Boutajangout et al. 2010 ; Lewis et al. 2000) . According to antibody databases (Antibodypedia and Alzforum), thousands of anti-tau antibodies are currently available, including >180 unique phospho-tau antibodies. However, few validation data have been published (Petry et al. 2014; Ercan et al. 2017; Mercken et al. 1992) , which indicated an alarming degree of non-specific binding frequently observed in phospho-tau antibodies. To prevent waste of resource and irreproducibility of results, a standard measure of specificity, equivalent to dissociation constants (K d ) for measuring affinity, is urgently needed. Ideally, this parameter should enable users to compare the specificity, identify the source of non-specificity, and clearly understand what is measured.
Existing specificity characterization methods relied on immunoblotting approaches using either synthetic peptides, cell lysates or extracted paired helical filament (PHF) tau (Petry et al. 2014; Ercan et al. 2017; Mercken et al. 1992) . Synthetic peptides allow binding measurement to exactly defined phosphorylation sites, but is prohibitively costly to cover all phospho-sites across the full-length tau. Cell lysates allow detection of non-specific binding to non-tau proteins (for example by using cell lysates from a tau knockout mouse) (Petry et al. 2014) , but cannot measure cross-reactivity to non-modified tau or other phosphorylation sites. Extracted PHF-tau from AD brain homogenates allows characterizing antibodies that do not recognize normal human adult tau and measuring the cross-reactivity to nonphospho-tau by treatment with phosphatase, but cannot capture the phospho-site specificity (Mercken et al. 1992 ).
Steinhilb and colleagues have generated transgenic flies expressing tau with alanine point mutations at several serine-proline and threonine-proline motifs of human tau (Steinhilb et al. 2007) . In this study, they used fly head extracts from these transgenic lines to perform western blotting using phospho-tau antibodies. In principle, this approach may be applied for validating phospho-tau antibodies. However, all of these approaches are not ideal for quantitative measurement due to frequent signal saturation in immunoblotting experiments (Janes 2015) . To fill this critical need, we introduce a parameter termed Φ (phi) that quantifies specificity of phospho-tau antibodies and establish a generalizable, robust assay to measure it.
The approach leverages flow cytometry for quantitative, multi-dimensional analysis of small changes in antibody binding to different cell populations. In a typical immunodetection experiment, signal from specific and non-specific binding cannot be distinguished. We sought to enable this distinction within a single sample, by generating two populations of cells with distinct fluorescence reporters. In one population of cells, the target protein (i.e., tau) is expressed as a fusion to the enhanced green fluorescent protein (EGFP) . In another population, tau containing a site-specific alanine mutation is expressed as a fusion to a near infra-red fluorescent protein (iRFP). The two populations of cells are mixed, and labeled with a phospho-specific antibody (Fig. 1) . For a phospho-site specific antibody, any binding to iRFPpositive cells is non-specific binding, enabling the measurement of the fraction of non-specific signal among all antibody binding signals. In order to ensure the measurement of cross-reactivity to nonphosphorylated tau, the experiment is repeated by replacing alanine mutant expressing cells with tau expressing cells (iRFP fused to wild-type tau) treated with the lambda protein phosphatase (λPP).
Analogous to the alanine mutation assay, binding to iRFP-positive cells is identified as non-specific signal. Based on these measurements, the fraction of non-specific signal is calculated, which is subtracted from 1 to obtain Φ . Therefore, Φ indicates the fraction of specific signal.
Using this measurement, we measured the specificity Φ of 7 commonly used phospho-tau antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1), in addition to others. Our results show that 5
antibodies (AT8, AT180, PHF-6, TG-3, and PHF-1) have Φ values near 1, indicating nearly perfect specificity. Antibodies AT270, AT100 showed weak but detectable non-specific binding to non-tau proteins in cells, with lower Φ values. This resulted in background fluorescence in flow cytometry and immunocytochemistry experiments. The non-specific binding also resulted in false positive detection in western blots, evidenced by additional bands appearing in cell lysates that do not contain human tau. To our knowledge, this is the first quantitative measurement of antibody specificity that enables specificity comparison with information on the source of non-specificity.
Methods

Cloning of recombinant constructs of tau and mutant tau
The following plasmids were obtained from Addgene: a mammalian expression vector pRK5 encoding EGFP tagged wild-type (WT) human tau (pRK5-EGFP-tau, # 46904, RRID: Addgene_46904), which contains four C-terminal repeat regions and lacks the N-terminal sequences (0N4R), a plasmid encoding iRFP (piRFP670-N1, # 44457, RRID: Addgene_45457), and a mammalian expression vector pcDNA3 encoding hemagglutinin tagged constitutively active glycogen synthase kinase-3β (GSK-3β) (S9A) (pcDNA3-GSK3β, # 14754, RRID: Addgene_14754). The EGFP in pRK5 vector was first replaced by iRFP to construct an iRFP tagged WT tau by golden gate assembly (pRK5-iRFP-tau) (Engler et al. 2008 ).
This assembly was performed using a Type IIs restriction enzyme BsaI (New England Biolabs # R3535) and T4 DNA ligase (New England Biolabs # M0202) (see Supp. Table 1 for primers used). Seven alanine mutant variants were generated in iRFP tagged tau to preclude phosphorylation. Alanine mutations were introduced to either Thr181, Ser202, Thr212/Ser214 (double alanine mutant), Thr231, Ser262, Ser396/Ser404 (double alanine mutant), or Ser404. For this, site-directed mutagenesis was conducted using overlap extension PCR (Pavoor et al. 2009 ) using the Phusion DNA polymerase (New England Biolabs # M0530) (see Supp. Table 2 . for primers used). Residue numbering of tau is according to the longest adult human brain tau isoform.
Cell culture and transfection
The human embryonic kidney (HEK) 293FT cells a high transfection efficiency isolate of the HEK293T cells were purchased from ThermoFisher (# R70007), and used without further authentication. The cell line is not listed as a commonly misidentified cell line by the International Cell Line Authentication
Committee. HEK293FT cells were grown in DMEM supplemented with 10 % fetal bovine serum. The cells were frozen at early passage and used for less than 2 months in continuous culture. HEK293FT cells were seeded in 24-well plate in the same number 2 days before plasmid transfection to reach 70 % confluency. The cells were then transfected with plasmid using the Lipofectamine 3000 reagent (Invitrogen # L3000001) according to the manufacturer's instructions.
Tau antibodies
10 phospho-tau antibodies raised against 7 phosphoepitopes in tau were validated for their specificity ( Table 1) . The following monoclonal antibodies were commercially available: AT270 (pThr181), AT8
(pSer202/pThr205), AT100 (pSer212/pSer214), AT180 (pThr231), PHF-6 (pThr231), 1H6L6 (pThr231), and anti-tau (pSer404). The following monoclonal antibodies were a gift of Dr. Peter Davies: TG-3 (pThr231 and conformation-specific) and PHF-1 (pSer396/pSer404). One purified rabbit polyclonal antibody anti-tau (pSer262) was purchased from Abcam. Tau-5 (Tau210-241, Invitrogen # AHB0042, AB_2536235) is a monoclonal antibody recognizing phosphorylated and non-phosphorylated tau isoforms. Purified single-chain antibody variable fragment (scFv) 3.24 targeting pThr231 was reported previously (Li et al. 2018) .
Quantitation of antibody specificity
Here we define a generally applicable parameter to quantify antibody specificity, based on general discussions regarding multi-partner protein interaction by Hall and Daugherty (Hall & Daugherty 2009 ).
If an antibody Ab is capable of binding to n different partners X 1 , X 2 , … X n as described by the following reactions,
the specificity of the interaction between Ab and X i can be defined as Φ where:
, where 1 indicates perfect specificity (Ab only reacts with its intended antigen X i ), and 0 indicates no interaction with X i . We used the following formula to quantify the specificity of phospho-tau antibodies:
indicates phosphorylated epitope sequences of tau at a defined site, and ‫ܣ‬ ݃ ௧ ௧
indicates overall potential partners including ܶ ܽ ‫ݑ‬ ௦
. In our assay, we determined the specificity using a threecolor labeling scheme, where the mixture of HEK293FT cells transiently expressing EGFP tagged WT human tau and iRFP tagged alanine mutant tau was incubated with a fluorescence-labeled antibody. In this case, the overall specificity Φ can be obtained by measuring the following parameter:
indicates antigen with an alanine mutation at the target phosphorylation site. Therefore, Φ ᇱ in this case indicates the fraction of total binding signal to the alanine mutant (non-specific binding signal from cells expressing the alanine mutant). Φ is defined as: 
Measurement of ࢶ : validation of phospho-tau antibody specificity
To measure Φ of phospho-tau antibodies, the HEK293FT cells were co-transfected with plasmids pRK5-EGFP-tau WT and pcDNA3-GSK3β using the lipofectamine method described above. In separate wells, HEK293FT cells were co-transfected with plasmids pRK5-iRFP-tau (alanine mutant) and pcDNA3-GSK3β. Cells were detached from 24-well plate using 0.05 % trypsin-EDTA (Gibco # 25300-054) for 10 min at 37 o C, then pelleted and washed 1x with ice-cold PBSCM (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 1 mM CaCl 2 , and 0.5 mM MgCl 2 , pH 7.4). The same number of cells from the two transfections were mixed and fixed in 4 % paraformaldehyde for 15 min at room temperature in a 1.5 mL microcentrifuge tube with gentle rotating. The fixed cells were permeabilized using PBSCM with 0.1 % Triton X-100 for 15 min at room temperature, then blocked in PBSG (PBSCM with 40 % goat serum, Gibco # 16210-064) for 30 min at room temperature with gentle rotating. For antibody staining, these cells were incubated overnight at 4 o C in dark with gentle rotating with tau antibodies diluted in PBSG (see Table 1 
Immunocytochemistry in HEK293FT cells
The HEK293FT 
Mouse hippocampus dissection
All procedures involving animals were in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the University of Connecticut Institutional Animal Care and Use Committee. Hippocampal dissection was performed according to the methods we have previously described (Cho et al. 2019; Klapoetke et al. 2014) . No sample calculation was performed, but was based on previous studies (Cho et al. 2019; Klapoetke et al. 2014) . Timed pregnant Swiss
Webster mice (gestational day 15) were purchased from Taconic. P0 or P1 postnatal mice (randomly selected from litter using simple randomization (Kim & Shin 2014) ) were placed on a physical barrier (such as a glove) on top of an ice slurry one at a time to induce hypothermia to reduce or terminate movement and bleeding, and decapitated. Hippocampus was dissected from 6 P0 or P1 postnatal mice in
Hank's balanced salt solution with 10 mM HEPES, 35 mM glucose, 1 mM kynurenic acid, and 10 mM MgCl 2 , pH 7.4. For dissociation, the hippocampal tissue was digested with 50 units of papain (Worthington Biochemical) for 8 min, and halted with ovomucoid trypsin inhibitor (Worthington Biochemical).
HEK293FT and mouse primary cell lysate preparation and western blotting
The following cell lysates were prepared: non-transfected HEK293FT cells, HEK293FT cells expressing EGFP only, HEK293FT cells expressing EGFP-tau WT, and dissociated mouse hippocampus. Cells were cultured to approximately 80 % confluency on 100 mm polystyrene tissue culture plates and scraped into 1 mL lysis buffer containing 150 mM NaCl, 5 mM EDTA, 50 mM Tris, 1 % Triton X-100, 0.5 % sodium deoxycholate, and 0.1 % sodium dodecyl sulfate, protease inhibitor cocktail (Sigma # P8340), and 
Experimental design
This study was not pre-registered.
Results
Phi: A generalizable parameter for measuring the specificity of phospho-tau antibodies
To quantify the specificity of phospho-tau antibodies, we developed a whole-cell based approach using flow cytometry (Fig. 1) . To probe the site-specificity of phospho-tau antibodies, we generated targeted alanine mutants at defined phosphorylation sites. HEK293FT cells were transiently transfected with either WT human tau (0N4R isoform) fused to the EGFP (EGFP-tau WT), or a point mutant (an alanine mutant at the phosphorylation site of interest) fused to the iRFP (iRFP-tau), in separate wells (Fig. 1a) . Previous reports indicated that endogenous tau expression is undetected in HEK293 cells (Kfoury et al. 2012; Liu et al. 2013) . In addition, when transfected with human tau, endogenous kinases in HEK293FT cells phosphorylated human tau (Camero et al. 2014; Houck et al. 2016) . Leveraging these facts, we developed a ratiometric assay to quantify the specificity of phospho-tau antibodies (Fig. 1a) . The EGFP-positive cells (expressing WT tau) and iRFP-positive cells (expressing a tau point mutant incapable of phosphorylation at a defined site) were mixed in same numbers and incubated with phospho-tau antibodies (Fig. 1a) . The EGFP (green channel) and iRFP (far-red channel) positive cells, and their antibody binding (red channel) were clearly distinguished using flow cytometry (Fig. 1b, left panel) . This assay quantifies the specific binding of the antibody to a defined phosphorylation site. In this assay, the phospho-tau antibody AT180, targeting phospho-threonine 231 (pThr231) Gotz et al. 2001; Nakamura et al. 2012) , showed almost exclusive labeling to the cells expressing EGFP-tau WT, and no detectable binding to iRFP-tau T231A (Fig. 1b) , indicating that AT180 binding requires pThr231.
In case an antibody shows non-specific binding to the alanine mutant at the target modification site, the antibody may be recognizing a phosphorylated residue at an off-target site. In addition, the absence of antibody binding to the alanine mutant does not exclude the possibility that binding to the non-modified tau is inhibited by the alanine mutation. In other words, the antibody may possess non-specific binding to unmodified tau, but may not bind to the alanine point mutant. To assess these possibilities, we transfected HEK293FT cells with either EGFP-tau WT or iRFP-tau WT separately and treated only the iRFP-tau WT expressing cells with λ PP (Fig. 1a) . As in the assay using the T231A mutant, AT180 showed exclusive binding to EGFP-tau WT cells (Fig. 1b, right panel) . This result provides further support that the AT180 antibody does not recognize the WT tau epitope without phosphorylation of Thr231.
We tested the assay (Fig. 1a) for its ability to discern phospho-specificity using 3 previously characterized anti-tau antibodies. Tau-5 is a pan-tau antibody that shows phosphorylation-independent binding (LoPresti et al. 1995; Carmel et al. 1996) , 3.24 is a high specificity scFv to pThr231 tau (Li et al. 2018) , and ab131354 targets pSer262 tau but have shown cross-reactivity to non-phosphorylated tau (Ercan et al. 2017) . Tau-5 indeed showed binding to both EGFP-tau WT and iRFP-tau WT treated with λ PP (Fig. 2a) . 3.24 showed binding to EGFP-tau WT, but not to iRFP-tau T231A or iRFP-tau WT treated with λ PP (Fig. 2b) , confirming its high specificity. ab131354 showed cross-reactivity to both iRFP-tau S262A and iRFP-tau WT treated with λ PP (Fig. 2c) , indicating that it is not specific to pSer262 tau. Table 1 , mean ± standard deviation from 2 independent experiments, all data points shown in Supp. Fig.   1 ), indicating nearly perfect phospho-site specificity towards pThr231 tau. The specificity Φ ୟ ୪ ୟ and Φ of ab131354 were 0.32 ± 0.02 and 0.37 ± 0.01, respectively, reflecting its poor specificity (Fig. 2) . Φ can be used as a general standard to measure and compare the specificity of post-translational modification (PTM)-site targeting antibodies.
Co-expression of glycogen synthase kinase-3β enhances tau phosphorylation
The assay developed here relies on intracellular phosphorylation of tau due to endogenous kinase activity in HEK293FT cells. Previous studies have found that tau expressed in HEK293 cells were phosphorylated at various sites, including S214, S262, S396/S404 (Ren et al. 2007) . A major advantage of our assay is the potential to co-express kinases to induce tau phosphorylation. Since many of the residues that are phosphorylated on tau are serine or threonine preceding a proline, we co-expressed glycogen synthase kinase (GSK)-3β, a proline-directed kinase, in HEK293FT cells to enhance tau phosphorylation. GSK-3β
phosphorylates tau at a wide range of sites found in Alzheimer's disease patients ).
Co-transfected cells showed a similar level of EGFP-tau WT expression (Fig. 3a, b) , but enhanced binding to the phospho-tau antibody AT8, which targets pSer202 (Pei et al. 1999; Sereno et al. 2009; Hernandez et al. 2003) (Fig. 3b) , indicating improved phosphorylation. Therefore, to enhance the detection of phospho-tau antibody binding, we co-transfected tau constructs with GSK-3β in subsequent experiments.
Quantifying the phospho-site specificity of commonly used phospho-tau antibodies
Using our assay, we quantified the specificity Φ of 7 widely used phospho-tau antibodies (AT270, AT8, AT100, AT180, PHF-6, TG-3, and PHF-1) as well as 2 additional phospho-tau antibodies (1H6L6 and pS404). Collectively these antibodies have been raised against 6 distinct phosphorylation sites (see Table approach in all antibodies except AT100 (Fig. 4, leftmost column) . Most antibodies showed exclusive binding to EGFP-tau WT, and no binding to the alanine point mutant at their corresponding target site or the iRFPtau WT treated with λ PP (Fig. 4, second (Fig. 4) . However, Φ = 0.99 ± 0.01 ( Table 1 ), indicating that the cross-reactivity was not detected in dephosphorylated cells.
and Φ together, the non-specific signal detected from AT270 was phosphorylationsensitive (see below for further characterization of non-specific binding in AT270). For AT100, the absence of binding to EGFP-tau WT cells suggests that the phospho-site (pThr212/pSer214) was not phosphorylated in HEK293FT cells, even with co-transfection of GSK-3β. Therefore, we were unable to measure the Φ values for AT100. Taken together, these results validate that the widely used phospho-tau antibodies AT8, AT180, PHF-6, TG-3, and PHF1 binds specifically to tau phosphorylated at the target site, but not to non-phosphorylated tau or phosphorylated tau at off-target sites.
Non-specific binding to cells in phospho-tau antibodies
For the antibody AT270, which showed lower Φ ୟ ୪ ୟ but high Φ , we observed a reproducible nonspecific binding to cells not expressing tau (dotted circles in Fig. 4) . Similar non-specific binding was detected with AT100, even though AT100 did not bind to EGFP-tau WT. Although not as prominent, a small fraction and weak level of non-specific binding to tau-negative cells was detected in antibodies 1H6L6 and TG-3 (closed circles in Fig. 4) Fig. 2) . No non-specific binding was detected in the secondary reagents, indicating that the non-specific binding observed was not due to secondary reagents. For AT270 and AT100, the population with non-specific binding separated clearly when cells were treated with λ PP (Fig. 4, 5a ). Since specific binding to phospho-tau in AT100 was not detected, we further analyzed the nonspecific binding of AT270. We also analyzed the non-specific binding of 1H6L6, which showed a weak level of non-specific binding (closed circles in Fig. 4 ). TG-3 was not included in this analysis since the fraction of tau-negative cells showing non-specific binding was even smaller. To further assess the nonspecific binding found in AT270 and 1H6L6, we conducted immunocytochemistry experiments.
Antibodies AT270 and 1H6L6 showed binding in cells not expressing EGFP-tau, while the highly specific antibody AT180 showed staining only to EGFP-tau positive cells (Fig. 5b) . To assess the broadness of proteins that cause the non-specific binding, we conducted western blotting experiments. We probed cell lysates from non-transfected, EGFP-transfected, EGFP-tau transfected cells as well as dissociated mouse hippocampus. In these experiments, antibodies AT270 and 1H6L6 showed bands in addition to a band corresponding to EGFP-tau (Fig. 5c) . In contrast, a single band corresponding to EGFP-tau was observed in AT180 (Fig. 5c) . For AT270, off-target bands found in HEK293FT cell lysates were also detected in WT mouse hippocampal cell lysate. Therefore, this non-specific binding was independent of species, leading to a non-specific band interfering with the mouse tau signal. However, for 1H6L6, the non-specific binding was not clearly detected in mouse hippocampal lysate, suggesting that the non-specific binding may be species or cell-type dependent. These results demonstrate that by using a whole-cell based approach, we have identified a source of non-specific binding in antibodies AT270 and 1H6L6 not observable when using peptides for specificity characterization.
Discussion
Site-specific phosphorylation of tau is critical in understanding the molecular biology of tau and is a welldefined target in neurodegeneration. The specificity of phospho-tau antibodies is critical for reproducible and sensitive detection (Li et al. 2018; Lothrop et al. 2013) . Phospho-tau antibodies should interact only with the target epitope sequence with site-specific phosphorylation, and not with nonphospho-tau or phospho-tau at off-target sites. In particular, considering the fact that phospho-tau antibodies are being developed for diagnostic tests and clinical trials as therapeutics, a standard measure of specificity is urgently needed (Chai et al. 2011; Boutajangout et al. 2011; Kayed 2010; Asuni et al. 2007; Boutajangout et al. 2010; Lewis et al. 2000) In this study, we developed a whole-cell based assay that enables robust measurement of the specificity of phospho-tau antibodies, and introduced the specificity parameter termed Φ . Φ is determined by measuring the fraction of binding signal from cross-reactivity to nonphospho-tau or off-target phosphorylation sites. indicates the phospho-site specificity of the antibody by measuring the fraction of non-specific binding to an alanine point mutant at the target phospho-site. Φ indicates the phospho-sensitivity of the antibody by measuring non-specific binding to de-phosphorylated tau. This approach can be easily adapted to other phosphorylated proteins, and potentially to other PTMs such as methylation and acetylation, allowing specificity quantification and comparison of any PTM-site specific antibody. In addition, the Φ values can be combined to a single parameter, to yield a single specificity parameter. For example,
In our calculation of the Φ values, we did not include the fluorescence signal detected from cells not expressing tau. Therefore, the small non-specific binding to cells we observed for antibody 1H6L6 (and to an even smaller degree in TG-3) is not reflected in their Φ values. As for AT270, the Φ value captured the non-specific binding to cells, since the non-specific binding was detected in the cells expressing the alanine mutant but was lost after de-phosphorylation with λ PP. We attempted to define another Φ parameter to quantify the non-specific binding to cells but the resulting values were inconsistent due to variations in the level of non-specific binding signal and fraction of cells showing binding.
Using our assay, we measured the Φ values of 10 phospho-tau antibodies, 7 of which have been used in hundreds of previous studies. Out of the 7, we quantified the specificity of 6 antibodies (AT270, AT8, AT180, PHF-6, TG-3, and PHF-1). We were unable to determine Φ values for AT100, due to lack of binding to tau expressed in HEK293FT cells. Endogenous kinases in HEK293FT cells phosphorylate human tau (Camero et al. 2014; Houck et al. 2016) . We showed that co-transfection of tau with GSK-3β led to increased phosphorylation of tau, but not for the AT100 target site (Thr212/Ser214). Previous studies have indicated that the AT100 epitope is formed only when a specific order of phosphorylation occurs (Zheng-Fischhofer et al. 1998 ). It has also been shown that Thr212 and Ser214 are sequentially phosphorylated by GSK-3β and protein kinase A (PKA), respectively (Zheng-Fischhofer et al. 1998) .
Considering that PKA is commonly expressed in cells, tau expressed in HEK293FT cells may only be phosphorylated at Ser214, leading to lack of AT100 binding. Tau phosphorylation may be enhanced by using mammalian brain extracts, which contain kinases that phosphorylate tau in vitro Lichtenberg-Kraag et al. 1992; Zheng-Fischhofer et al. 1998) .
Out of the 6 phospho-tau antibodies (AT270, AT8, AT180, PHF-6, TG-3, and PHF-1), all but AT270 had Φ values close to 1, indicating near-perfect specificity. For AT270, a weak, but reproducible binding was detected to tau-negative HEK293FT cells (Fig. 4) . This non-specific binding was consistently detected in immunocytochemistry experiments, leading to distinct perinuclear non-specific binding (Fig. 5b) .
Western blotting with AT270 revealed additional bands consistently present in non-transfected HEK293FT cell lysate as well as primary WT mouse hippocampal lysate (Fig. 5c) . A previous study found multiple bands when probing WT mouse brain lysate (Petry et al. 2014) . The same study also found non-specific binding in antibodies AT8, AT180, and TG-3, using cell lysate prepared from tau knockout mice. However, this non-specific binding was not due to the antibodies themselves, and was eliminated by switching secondary reagents (Petry et al. 2014) . We found that the two Φ values for (Egelhofer et al. 2011; Bock et al. 2011; Fuchs et al. 2011) . Synthetic peptides and peptide arrays were also used for specificity analysis of phospho-tau antibodies (Ercan et al. 2017) . The limitation of this approach is the high cost of synthesizing peptides in order to comprehensively cover tau phosphorylation sites. Moreover, short peptides do not have strong binding to conformation-sensitive phospho-tau antibodies, such as TG-3 (Gotz et al. 2001) . Our approach allows assessment of binding to full-length tau with defined sequence variations, and can be co-expressed with kinases to induce tau phosphorylation. Using our approach, the specificity of the conformation-sensitive pT231 tau antibody TG-3 was also successfully determined ( Fig.   4 and Table 1 ). Libraries of tau mutations may be generated, and deep sequencing approaches can be used for de novo identification of anti-tau antibodies. Our approach also revealed non-specific binding of antibodies to irrelevant cellular proteins. We found that the source of non-specific binding for AT270 is conserved across HEK293FT cells and mouse primary hippocampal cells, but was not conserved for 1H6L6, indicating cell-type and species sensitivity of non-specific binding. Further analyses using immunoprecipitation and mass spectrometry may allow the identification of the cross-reactive proteins.
Since the cross-reactivity of antibodies would be dependent on the affinity to the off-target sites or molecules, it is possible that the Φ values are dependent on antibody concentration. In particular, the Φ values may decrease upon increasing antibody concentration. In our experiments, we used antibody concentrations typically used for cell labeling experiments (2 μ g/mL, Table 1 ). Since we observed high antibody binding signal in these experiments for all antibodies tested except AT100 (which showed nonspecific binding to cells), we did not attempt to increase the antibody concentration. Also, all antibodies that showed binding had near-perfect specificity, except AT270 and ab131354. Lowering the antibody concentration for these antibodies resulted in a significant decrease in antibody binding, and did not result in improvement of Φ values (data not shown). Even for the high specificity antibodies, users should be cautious when using them at higher concentrations than what is listed in Table 1 , since that may result in increased non-specific binding.
In summary, our study provided a whole-cell based approach to validate the specificity of phospho-tau antibodies. Using this assay, we determined the parameter Φ for phospho-tau antibodies, that enable quantitative comparison of specificity. We anticipate that this parameter will be widely adopted in guiding users of the specificity of phospho-tau antibodies, and potentially PTM-specific antibodies in general. 
